Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

The promise of precision medicine

Precision medicine is set to revolutionise patient care

- PMLiVE

Fishawack Health adds The Hive Health Group to its network

The Hive Health Group is based in London and New York

- PMLiVE

Havas Just:: names Nicole Yost chief executive officer

Yost will replace Jennie Talman, who is stepping aside after 15 years

- PMLiVE

Researchers suggest delaying second dose of Pfizer/BioNTech jab to protect more people

Canada-based researchers Skowronski and De Serres say first dose is ‘highly protective’

- PMLiVE

Henry Skinner has been appointed as the first CEO of the AMR Action Fund

The AMR Action Fund is aiming to strengthen and accelerate antibiotic development

- PMLiVE

Don’t hesitate, vaccinate!

Different communities may have different questions or information needs about COVID-19 vaccination

- PMLiVE

Richest countries are on course to purchase one billion excess COVID-19 vaccines, new analysis finds

Report from the ONE Campaign considered vaccine supply deals agreed by G20 countries and the EU

- PMLiVE

Novavax to provide 1.1 billion COVID-19 vaccine doses to COVAX

Memorandum of understanding announced between Novavax, Gavi and the Vaccine Alliance

- PMLiVE

AMR Action Fund raises $140m from new investors to tackle antimicrobial resistance

New investment adds to initial $1bn raised at the Fund's launch last year

Risk Management, Ethics, and Compliance Considerations in the New Normal

Myriam Prescott, Head of Ethics, Risks and Compliance - Oncology, Novartis Canada, dissects the importance of effective patient engagement and strong compliance & monitoring programs. We also dive into the...

Impetus Digital

A Deep-Dive into the COVID-19 Pandemic and its Secondary Effects

Dr. Farah Fourcand, Author of Pandemic Manifesto, shares her experience working on the frontlines of the COVID-19 pandemic. She also dives into the psychological impact of COVID-19, lessons learned from the...

Impetus Digital

- PMLiVE

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Companies will co-develop molecules for the treatment of immunological and neurodegenerative diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links